Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

Clinical Outcomes

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

The verdict raises pressure on UK regulators weighing NHS access.

Sanofi’s Efdoralprin Alfa Shows Superior Biomarker Response to Plasma Therapy in Phase 2 AATD Trial